OpenMedium-term (3–5 yrs)Treatment Study
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
For Condition: Hypertriglyceridemia
ID: NCT07199309
Horizon Patient Guidance Summary
Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:
How it’s taken
Injections / IV Shots
Expected Availability Horizon
Medium-term (3–5 yrs away)
StageMiddle Clinical Stage: Designed to check if the treatment actively works for the condition in moderate groups (100–300 people). Gathers early success indicators.
EligibleThis study is looking exclusively for patients diagnosed with the condition.
About This Clinical Trial
The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
Study Timeline & Quick Facts
Trial Status
Open — Looking for Participants
Total Target Enrollment
30 patients (Estimated)
Study Start Date
2025-09-26
Est. Primary Completion
2026-07
Tested Drugs & Treatment Groups
DRUGMAR001
Subcutaneous Injection
DRUGPlacebo
Subcutaneous Injection
Treatment Arms Description
EXPERIMENTALMAR001 Dose
Subcutaneous Injection
PLACEBO_COMPARATORMatching Placebo
Can I Join This Study?
Suitable For
Everyone welcome
Ages Welcome
Between 18 Years and 75 Years
Full Criteria Checklist
Who Can Join
- Willingness to provide informed consent and comply with the intervention and all study assessments
- Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period
- HbA1c ≥ 5.7% and ≤ 8.5%
- Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study
- Stable drug regimen (appropriate if relevant) prior to screening visit and no planned changes during screening or trial participation
Who Cannot Join
- Acute or chronic liver disease
- Diabetes medications (other than metformin)
- History of type 1 diabetes mellitus or history of diabetic ketoacidosis
- Newly diagnosed T2DM
- Participants with known active hepatitis A, B, or C
- Participants who are known to have uncontrolled human immunodeficiency virus (HIV) infection
- Uncontrolled hypothyroidism
- Any condition that prevents the participant from complying with study procedures
What is this Study Measuring?
Primary Outcome Measures
- Change from baseline in TG area under the curve after a mixed meal — Time Frame: 12 weeks
- Change from baseline in peak plasma TG concentration after a mixed meal — Time Frame: 12 weeks
View Secondary Outcome Measures (2)
- Change from baseline in RC area under the curve after a mixed meal — Time Frame: 12 weeks
- Change from baseline in peak plasma RC concentration after a mixed meal — Time Frame: 12 weeks
Where to Participate
This trial is recruiting at 1 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:
Show All 1 Facilities & Contact Sites
Marea Site 301
Chula Vista, California, United States
Status: Open
Trial Design & Scientific Setup
Allocation
randomized
Intervention Model
parallel
Primary Purpose
treatment
Masking
quadruple (participant, care_provider, investigator, outcomes_assessor)
Sponsoring Teams & Contacts
Lead Sponsoring Institution
Marea Therapeutics
Primary Research Contact
Clinical Trial Application Copilot
Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!
Generated Professional Email Draft:
Draft ready to copy & send
Subject: Inquiry about clinical trial enrollment: NCT07199309 - A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Dear Study Coordinator / Research Team,
I hope this message finds you well.
My name is [Your Name], and I am writing to express my strong interest in participating in the clinical trial titled "A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol" (NCT ID: NCT07199309).
I am [Age] years old and have been diagnosed with Hypertriglyceridemia. I have reviewed the eligibility criteria for this study on Med Code Info and believe I may be a suitable candidate.
Could you please let me know if this study is actively enrolling patients at any site near my location, and what the next steps are to undergo screening?
Thank you for your time and research efforts.
Warm regards,
[Your Name]
View Official Medical/Scientific Title
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of MAR001 on Postprandial Lipids in Patients With Elevated Triglycerides and Remnant Cholesterol